eli lilly glp-1 receptor agonist medications news FDA just approved orforglipron (Foundayo), Lilly's oral for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), FDA approves Foundayo, an oral
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15


























